Search Results
You are looking at 1 - 2 of 2 items for
- Author or Editor: Patricia Shewen x
- Refine by Access: All Content x
Abstract
Objective—To develop a method for experimental induction of equine rhinitis A virus (ERAV) infection in equids and to determine the clinical characteristics of such infection.
Animals—8 ponies (age, 8 to 12 months) seronegative for antibodies against ERAV.
Procedures—Nebulization was used to administer ERAV (strain ERAV/ON/05; n = 4 ponies) or cell culture medium (control ponies; 4) into airways of ponies; 4 previously ERAV-inoculated ponies were reinoculated 1 year later. Physical examinations and pulmonary function testing were performed at various times for 21 days after ERAV or mock inoculation. Various types of samples were obtained for virus isolation, blood samples were obtained for serologic testing, and clinical scores were determined for various variables.
Results—ERAV-inoculated ponies developed respiratory tract disease characterized by pyrexia, nasal discharge, adventitious lung sounds, and enlarged mandibular lymph nodes. Additionally, these animals had purulent mucus in lower airways up to the last evaluation time 21 days after inoculation (detected endoscopically). The virus was isolated from various samples obtained from lower and upper airways of ERAV-inoculated ponies up to 7 days after exposure; this time corresponded with an increase in serum titers of neutralizing antibodies against ERAV. None of the ponies developed clinical signs of disease after reinoculation 1 year later.
Conclusions and Clinical Relevance—Results of this study indicated ERAV induced respiratory tract disease in seronegative ponies. However, ponies with neutralizing antibodies against ERAV did not develop clinical signs of disease when reinoculated with the virus. Therefore, immunization of ponies against ERAV could prevent respiratory tract disease attributable to that virus in such animals.
Abstract
Objective—To characterize the impact of Mannheimia haemolytica infection on feed intake and weight gain in feedlot heifers and to evaluate the clinical efficacy of isoflupredone acetate administered in combination with oxytetracycline.
Animals—96 weanling heifers in a research feedlot facility.
Procedures—Bronchopneumonia was induced by intrabronchial infusion of M haemolytica. Control heifers underwent a sham procedure. Infected heifers were treated with oxytetracycline alone or in combination with isoflupredone acetate (OXY-ISO) or with nothing. Clinical variables were recorded daily for 7 days following disease induction, and feedlot performance indices were measured over a 12-week period.
Results—Infection caused a reduction in dry-matter intake and average daily gain (ADG) in heifers that received no treatment. Oxytetracycline treatment alone did not prevent reductions in feed intake and ADG during the first week after infection was induced, whereas OXY-ISO treatment did prevent these reductions. Treatment with OXY-ISO also resulted in faster clinical improvement. No significant differences were evident between the oxytetracycline and OXY-ISO groups with respect to dry-matter intake or ADG throughout the study period.
Conclusions and Clinical Relevance—Isoflupredone acetate appeared to be a useful clinical adjunct to treatment with oxytetracycline in cattle with acute M haemolytica bronchopneumonia.
